


(I)

{wherein, X is a single bond, $-\text{CH}_2\text{COO}-$, $-\text{CONH}-$, or $-\text{NHCO}-$, R_1 is an alkyl group having 1-10 carbon atoms and optionally having substituent(s), an aryl group optionally having substituent(s), or $-\text{Y}-\text{W}-\text{Z}-\text{Ar}$ wherein Y and Z are each a single bond or an alkylene group having 1-6 carbon atoms and optionally having substituent(s), W is an oxygen atom, a sulfur atom or $\text{N}(\text{R}_4)$, R_4 is a hydrogen atom or an alkyl group having 1-6 carbon atoms, Ar is an aryl group optionally having substituent(s), R_2 is an alkyl group having 1-6 carbon atoms and optionally having substituent(s), R_3 is a hydroxyl group, and n is 0, 1 or 2}.

5. A therapeutic agent for a disease or tissue damage associated with failure of cellular proliferation, comprising a compound represented by the following formula (I) or a salt thereof:



(I)


{wherein, X is a single bond, $-\text{CH}_2\text{COO}-$, $-\text{CONH}-$, or $-\text{NHCO}-$, R_1 is an alkyl group having 1-10 carbon atoms and optionally having substituent(s), an aryl group optionally having substituent(s), or $-\text{Y}-\text{W}-\text{Z}-\text{Ar}$ wherein Y and Z are each a single bond or an alkylene group having 1-6 carbon atoms and optionally having substituent(s), W is an oxygen atom, a sulfur atom or $\text{N}(\text{R}_4)$, R_4 is a hydrogen atom or an alkyl group having 1-6 carbon atoms, Ar is an aryl group optionally having substituent(s), R_2 is an alkyl group having 1-6 carbon atoms and optionally having substituent(s), R_3 is a hydroxyl group, and n is 0, 1 or 2}.

6. The therapeutic agent according to claim 5, wherein the disease or tissue damage associated with failure of cellular proliferation is a disease associated with suppressed nuclear translocation of YAP and/or TAZ.

7. The therapeutic agent according to claim 5, wherein the disease or tissue damage associated with failure of cellular proliferation is selected from the group consisting of inflammatory disease, inflammatory bowel disease, neurodegenerative disease, immune-nerve disease, muscular dystrophy, myopathy, trauma, burn, chemical burn, skin ulcer, traumatic ulcer, lower leg ulcer, frostbite ulcer, immune-ulcer, postherpetic ulcer, radiation ulcer, pressure ulcer, diabetic skin ulcer, giant pigmented nevus, scar, disorder due to tattoo, vitiligo vulgaris, leukopathia, spinal cord damage, muscle damage, liver failure, drug-induced hepatopathy, alcohol-induced hepatopathy, ischemic hepatopathy, viral

hepatopathy, autoimmune hepatopathy, acute hepatitis, chronic hepatitis, cirrhosis, skin damage, brain edema, myocardial infarction, cerebral hemorrhage, and cerebral infarction.

8. A proliferation promoter of a cell or tissue for a transplantation treatment, comprising a compound represented by the following formula (I) or a salt thereof:



(I)

{wherein, X is a single bond, $-\text{CH}_2\text{COO}-$, $-\text{CONH}-$, or $-\text{NHCO}-$, R_1 is an alkyl group having 1-10 carbon atoms and optionally having substituent(s), an aryl group optionally having substituent(s), or $-\text{Y}-\text{W}-\text{Z}-\text{Ar}$ wherein Y and Z are each a single bond or an alkylene group having 1-6 carbon atoms and optionally having substituent(s), W is an oxygen atom, a sulfur atom or $\text{N}(\text{R}_4)$, R_4 is a hydrogen atom or an alkyl group having 1-6 carbon atoms, Ar is an aryl group optionally having substituent(s), R_2 is an alkyl group having 1-6 carbon atoms and optionally having substituent(s), R_3 is a hydroxyl group, and n is 0, 1 or 2}.

9. The inhibitor, therapeutic agent or proliferation promoter according to claim 1, wherein X is $-\text{NHCO}-$.

10. The inhibitor, therapeutic agent or proliferation promoter according to claim 1, wherein R_2 is an alkyl group having 1-6 carbon atoms, and n is 0.

11. The inhibitor, therapeutic agent or proliferation promoter according to claim 1, wherein R_1 is $-\text{Y}-\text{W}-\text{Z}-\text{Ar}$, Y is a methylene group optionally having an alkyl group having 1-6 carbon atoms, W is $\text{N}(\text{R}_4)$, Z is a single bond, and Ar is an aryl group optionally having a halogen atom, a hydroxyl group, an alkyl group having 1-6 carbon atoms or an alkoxy group having 1-6 carbon atoms.

12. The inhibitor, therapeutic agent or proliferation promoter according to claim 1, wherein R_2 is a methyl group, an ethyl group, or an isobutyl group, n is 0,

Ar is a phenyl group optionally substituted by a hydroxyl group or a methyl group, and

Y is a methylene group optionally substituted by a methyl group or an ethyl group.

13. The inhibitor, therapeutic agent or proliferation promoter according to claim 1, wherein the compound represented by the formula (I) is a compound selected from the group consisting of the following:

